scholarly journals Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders

2009 ◽  
Vol 63 (4) ◽  
pp. 440-448 ◽  
Author(s):  
Ying-Ching Lai ◽  
Ming-Chyi Huang ◽  
Chun-Hsin Chen ◽  
Chang-Jer Tsai ◽  
Chun-Hung Pan ◽  
...  
Keyword(s):  
Chinese Patients ◽  
Schizoaffective Disorders ◽  
Long Acting

Efficacy and Quality of Life in Patients with Schizophrenia and Schizoaffective Disorders Treated with Long-acting Paliperidone Palmitate: A Naturalistic Longitudinal Study

2017 ◽  
Vol 41 (S1) ◽  
pp. S274-S274
Author(s):  
A. Nivoli ◽  
L. Folini ◽  
L. Floris ◽  
M. Antonioli ◽  
F. Pinna ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rating Scale ◽  
Paliperidone Palmitate ◽  
Psychiatric Clinic ◽  
Schizoaffective Disorders ◽  
Significant Difference ◽  
Quality Of Life Index ◽  
Long Acting ◽  
Over Time

IntroductionIntramuscular paliperidone palmitate (PP) is a long-acting, atypical antipsychotic for ntramuscular (IM) administration in the treatment of patients with schizophrenia.ObjectiveTo study efficacy and quality of life in patients with schizophrenia and schizoaffective disorders treated with long-acting paliperidone palmitate.MethodA non-randomized, prospective naturalistic study was performed in out-patients with schizophrenia and schizoaffective disorder unsuccessfully treated with oral antipsychotics. Efficacy of PP over time was evaluated by using BPRS 24-items (Brief Psychiatric Rating Scale) Quality of life was evaluated by the QL-Index (Quality of life Index) at T0 and at most recent visit (T1).ResultsData were available for 16 outpatients consecutively prescribed PP and naturalistically treated attending at the Psychiatric Clinic, University of Sassari. Patients were predominantly male (n = 9; 56.2%), with schizophenia (n = 10; 62.5%). Three patients dropped out (18.8%). Mean time on PP treatment was 870.0 days (sd 217.02) at a mean PP maintenance dose of 97.82 ± 37.17 mg eq. BPRS mean total score at T0 was 55 (sd 14.5) and at T1 was 44.8 (sd 11.8). Ql-Index mean total score was 5 (sd 1.6) at T0 and 7.2 (sd 2.4) at T1. Paired sample test showed a statistically significant difference in deacreasing symptoms at BPRS over time (P = 0.009) and in improving Quality of life at QL-Index (P = 0.017). The analyses showed a significant improving at the following BPRS sub-items: Depression (P = 0.021), Hostility (P = 0.022), Suspiciousness (P = 0.005), Hallucinations (P = 0.050), Unusual thought content (P = 0.029), Self-neglet (P = 0.028), Conceptual disorganization (P = 0.044), Emotional withdrawal (P = 0.028) and Distractibility (P = 0.014).Disclosure of interestThe authors have not supplied their declaration of competing interest.

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

2005 ◽  
Vol 19 (5_suppl) ◽  
pp. 5-14 ◽  
Author(s):  
E. Parellada ◽  
R. Andrezina ◽  
V. Milanova ◽  
P. Glue ◽  
M. Masiak ◽  
...  
Keyword(s):  
Symptom Improvement ◽  
Treatment Change ◽  
Open Label ◽  
Schizoaffective Disorders ◽  
Direct Initiation ◽  
Syndrome Scale ◽  
Previous Medication ◽  
Long Acting ◽  
Negative Syndrome ◽  
Early Phases

The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (≤ 3 years). Patients who required a treatment change received RLAI (2-weekly gluteal injections of 25, 37.5 or 50mg, per clinical judgement), without an oral risperidone run-in phase. A total of 382 patients were included in this 6-month open-label study; 73% of patients completed the study. A total of 84% had schizophrenia with a median duration of 1.0 year since diagnosis. Previous medications were mainly atypical antipsychotics (70%) and depot neuroleptics (24%). The main reasons for treatment change were non-compliance (42%) and insufficient efficacy (31%) of previous medication. The total Positive and Negative Syndrome Scale (PANSS) and all its subscale scores improved significantly (p ≤ 0.0001), with 40% of patients showing a 20% improvement on total PANSS. Global Assessment of Functioning, quality of life, patient satisfaction and movement disorders also improved significantly. Tolerability of RLAI was generally good and no unexpected adverse events were reported. The ensured delivery of medication with RLAI resulted in significant symptom improvement in this patient population. Direct initiation of RLAI is well accepted by patients. RLAI might represent a novel option for patients in the early phases of psychosis.

P.3.c.008 Open-label over effectiveness of long-acting risperidone as maintenance therapy of bipolar and schizoaffective disorders

2008 ◽  
Vol 18 ◽  
pp. S409
Author(s):  
P. Castro-Loli ◽  
A. Benabarre ◽  
A. Martinez-Aran ◽  
J. Sanchez-Moreno ◽  
M. Salamero ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Open Label ◽  
Schizoaffective Disorders ◽  
Long Acting

scholarly journals Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e043664
Author(s):  
Ahmed Salem ◽  
Heng Zhong ◽  
Mafalda Ramos ◽  
Mark Lamotte ◽  
Hao Hu
Keyword(s):  
Maintenance Therapy ◽  
Economic Impact ◽  
Cost Savings ◽  
Chinese Patients ◽  
Base Case ◽  
Chronic Obstructive ◽  
Health States ◽  
Health Economic Analysis ◽  
Discharged Patients ◽  
Long Acting

ObjectivesChronic obstructive pulmonary disease (COPD) exacerbations requiring hospitalisation are a considerable burden, both clinically and economically. Although long-acting maintenance therapy is recommended in both the GOLD (Global Initiative for Chronic Obstructive Lung Disease) and Chinese COPD guidelines, proper implementation is lacking. The objective of this study was to assess the clinical and economic impact of prescribing long-acting maintenance therapy to discharged patients with COPD after hospitalisation for an exacerbation in China by using an outcomes model.DesignThis health economic analysis was conducted using a Markov cohort model from the Chinese healthcare payer perspective. Two health states (alive and dead) were modelled, and exacerbations were included as possible events.SettingThe target population was Chinese patients with COPD, >40 years of age, who were hospitalised for an exacerbation, with 1 year of follow-up. A recent COPD national prevalence study was referenced for population calculations.InterventionA hypothetical future scenario, where 100% of patients would receive long-acting maintenance therapy after hospitalisation for an exacerbation, was compared with the current scenario, in which only 38.5% of patients are receiving long-acting maintenance therapy after hospitalisation.Outcome measuresNumber of exacerbations, deaths and medical costs were measured.ResultsWe estimated that there were approximately 4 million Chinese patients with COPD who were hospitalised annually due to an exacerbation. By prescribing long-acting maintenance therapy, our model predicted that 917 360 exacerbations and 4034 deaths could be avoided, translating into cost savings of ¥3.5 billion (US$0.5 billion). Scenario analysis also showed that if the rate of exacerbations requiring hospitalisation was higher than our base case analysis, cost savings could reach up to ¥10.7 billion (US$1.5 billion).ConclusionAdministering long-acting maintenance therapy to more patients with COPD at hospital discharge could considerably reduce exacerbations and healthcare spending in China.

Sign in / Sign up

Export Citation Format

Share Document